Recent Developments in the Pharmacological Reduction of Blood Glucose in Patients With Type 2 Diabetes
- John R. White, Jr., PharmD, PA-C and
- R. Keith Campbell, RPh, MBA, CDE
Abstract
IN BRIEF
The pharmacological management of type 2 diabetes has changed dramatically in the past few years with the introduction of many new medications, including α-glucosidase inhibitors, a biguanide, the thiazolidinediones, insulin analogs, meglitinides, and d-phenylalanine derivatives. These new agents have dramatically increased the number of options available to providers and patients. Combination therapy has become commonplace for the management of hyperglycemia in patients with type 2 diabetes. This article briefly reviews some of the more recent pharmacological advances in diabetes care.
Footnotes
-
John R. White, Jr., PharmD, PA-C, is an associate professor at Washington State University College of Pharmacy in Spokane. R. Keith Campbell, RPh, MBA, CDE, is a professor and associate dean at Washington State University College of Pharmacy in Pullman.
-
Note of disclosure: Dr. White has received honoraria for speaking engagements from Novartis, Pfizer, Aventis, and Bristol Myers Squibb. Dr. Campbell has received honoraria for speaking engagements from Eli Lilly, Aventis, and Merck Pharmaceuticals and is a paid consultant for Eli Lilly. All of these companies manufacture and market pharmaceutical products for the treatment of diabetes.
- American Diabetes Association
